Switching from Neutral Protamine Hagedorn Insulin to Insulin Glargine 300 U/mL Improves Glycaemic Control and Reduces Hypoglycaemia Risk: Results of a Multicentre, Prospective, Observational Study.
Aged
Blood Glucose
/ metabolism
Diabetes Mellitus, Type 2
/ blood
Drug Substitution
Female
Glycated Hemoglobin
/ metabolism
Glycemic Control
Humans
Hypoglycemia
/ blood
Hypoglycemic Agents
/ adverse effects
Insulin Glargine
/ adverse effects
Insulin, Isophane
/ adverse effects
Male
Middle Aged
Prospective Studies
Treatment Outcome
Journal
Journal of diabetes research
ISSN: 2314-6753
Titre abrégé: J Diabetes Res
Pays: England
ID NLM: 101605237
Informations de publication
Date de publication:
2020
2020
Historique:
received:
21
01
2020
accepted:
28
03
2020
entrez:
28
4
2020
pubmed:
28
4
2020
medline:
17
2
2021
Statut:
epublish
Résumé
Type 2 diabetes mellitus (T2DM) is a major cause of morbidity and mortality worldwide and is an important public health issue. A significant proportion of insulin-treated patients with T2DM do not reach target glycated haemoglobin (HbA1c) values, which ultimately increases their risk of long-term microvascular and macrovascular complications. One potential option to improve diabetes control in these patients may be the use of new insulin formulations including second-generation basal insulin analogues such as insulin glargine 300 U/mL (Gla-300). Several published randomised controlled trials have assessed the clinical effectiveness of Gla-300, mostly versus insulin glargine 100 U/mL as well as insulin degludec. However, there is limited information about the real-world effectiveness of Gla-300 when patients are transitioned directly from neutral protamine Hagedorn (NPH) human basal insulin. The primary objective of this study was to evaluate the effectiveness of Gla-300, defined as the percentage of participants with an HbA1c reduction of ≥0.5%, 6 months after switching from NPH insulin, in participants with T2DM. Secondary objectives included the safety assessment based on the percentage of patients experiencing ≥1 episodes and the number of hypoglycaemic episodes by category: severe, symptomatic, symptomatic confirmed, diurnal or nocturnal, change in body weight, and insulin dose. A total of 469 participants completed the 6-month observation period. Mean baseline HbA1c was 9.19%. The percentage of participants with a ≥0.5% improvement in HbA1c from baseline was 71.7% at 6 months. Mean HbA1c decreased at 3 and 6 months by 0.77% (±0.98) and 1.01% (±1.12), respectively (
Identifiants
pubmed: 32337298
doi: 10.1155/2020/8751348
pmc: PMC7168722
doi:
Substances chimiques
Blood Glucose
0
Glycated Hemoglobin A
0
Hypoglycemic Agents
0
hemoglobin A1c protein, human
0
Insulin Glargine
2ZM8CX04RZ
Insulin, Isophane
53027-39-7
Types de publication
Journal Article
Multicenter Study
Observational Study
Langues
eng
Sous-ensembles de citation
IM
Pagination
8751348Informations de copyright
Copyright © 2020 B. Wolnik et al.
Déclaration de conflit d'intérêts
The authors declare that they have no conflicts of Interests.
Références
Diabetes Care. 2003 Jun;26(6):1902-12
pubmed: 12766131
BMJ Open. 2016 Feb 15;6(2):e009421
pubmed: 26880669
Diabetes Care. 2019 Jun;42(6):994-1004
pubmed: 31110117
Diabetes Care. 2013 May;36(5):1384-95
pubmed: 23589542
Ann Pharmacother. 2015 Oct;49(10):1153-61
pubmed: 26238470
Diabetes Obes Metab. 2018 Mar;20(3):541-548
pubmed: 28862801
Diabetes Care. 2014 Oct;37(10):2755-62
pubmed: 25078900
Diabetes Care. 2017 Apr;40(4):468-475
pubmed: 27659408
Diabetes Res Clin Pract. 2016 May;115:31-8
pubmed: 27242120
Diabetes Ther. 2019 Apr;10(2):617-633
pubmed: 30767173
Acta Diabetol. 2015 Aug;52(4):649-62
pubmed: 25585592
Adv Ther. 2018 Jan;35(1):43-55
pubmed: 29313285
Int J Clin Pract Suppl. 2009 Oct;(164):6-10
pubmed: 19751453
Endokrynol Pol. 2014;65(3):158-68
pubmed: 24971915